Report Detail

Request for Sample of this report

Pharma & Healthcare Global Interleukin Inhibitors for Psoriasis Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4749422
    • |
  • 05 October, 2026
    • |
  • Global
    • |
  • 110 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Interleukin Inhibitors for Psoriasis market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Interleukin inhibitors for psoriasis refer to a class of biologic medications that specifically target and inhibit interleukins.Psoriasis is characterized by an overactive immune response that leads to excessive production of cytokines such as interleukin-12 (IL-12),interleukin-23 (IL-23),and interleukin-17A(IL-17A), among others.IL inhibitors work by blocking these specific interleukins or their receptors,thereby interrupting the inflammatory cascade responsible for the skin lesions and systemic symptoms associated with psoriasis.
This report is a detailed and comprehensive analysis for global Interleukin Inhibitors for Psoriasis market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Interleukin Inhibitors for Psoriasis market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Interleukin Inhibitors for Psoriasis market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Interleukin Inhibitors for Psoriasis market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Interleukin Inhibitors for Psoriasis market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Interleukin Inhibitors for Psoriasis
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Interleukin Inhibitors for Psoriasis market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Dalian Yawei Pharmaceutical, Janssen Biotech, Teva, UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, Kyowa Kirin, Samsung Bioepis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Interleukin Inhibitors for Psoriasis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Interleukin-8 Inhibitors
Interleukin-12 Inhibitors
Interleukin-17 Inhibitors
Interleukin-23 Inhibitors
Other
Market segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Major players covered
Dalian Yawei Pharmaceutical
Janssen Biotech
Teva
UCB
Eli Lilly
Novartis
Ortho Dermatologics
LEO Pharma
Kyowa Kirin
Samsung Bioepis
Sun Pharma
China Medical System
Almirall
AbbVie Biotechnology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Interleukin Inhibitors for Psoriasis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Interleukin Inhibitors for Psoriasis, with price, sales quantity, revenue, and global market share of Interleukin Inhibitors for Psoriasis from 2021 to 2026.
Chapter 3, the Interleukin Inhibitors for Psoriasis competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Interleukin Inhibitors for Psoriasis breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Interleukin Inhibitors for Psoriasis market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Interleukin Inhibitors for Psoriasis.
Chapter 14 and 15, to describe Interleukin Inhibitors for Psoriasis sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Interleukin Inhibitors for Psoriasis Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Interleukin-8 Inhibitors
    • 1.3.3 Interleukin-12 Inhibitors
    • 1.3.4 Interleukin-17 Inhibitors
    • 1.3.5 Interleukin-23 Inhibitors
    • 1.3.6 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Interleukin Inhibitors for Psoriasis Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Other
  • 1.5 Global Interleukin Inhibitors for Psoriasis Market Size & Forecast
    • 1.5.1 Global Interleukin Inhibitors for Psoriasis Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Interleukin Inhibitors for Psoriasis Sales Quantity (2021-2032)
    • 1.5.3 Global Interleukin Inhibitors for Psoriasis Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Dalian Yawei Pharmaceutical
    • 2.1.1 Dalian Yawei Pharmaceutical Details
    • 2.1.2 Dalian Yawei Pharmaceutical Major Business
    • 2.1.3 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product and Services
    • 2.1.4 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Dalian Yawei Pharmaceutical Recent Developments/Updates
  • 2.2 Janssen Biotech
    • 2.2.1 Janssen Biotech Details
    • 2.2.2 Janssen Biotech Major Business
    • 2.2.3 Janssen Biotech Interleukin Inhibitors for Psoriasis Product and Services
    • 2.2.4 Janssen Biotech Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Janssen Biotech Recent Developments/Updates
  • 2.3 Teva
    • 2.3.1 Teva Details
    • 2.3.2 Teva Major Business
    • 2.3.3 Teva Interleukin Inhibitors for Psoriasis Product and Services
    • 2.3.4 Teva Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Teva Recent Developments/Updates
  • 2.4 UCB
    • 2.4.1 UCB Details
    • 2.4.2 UCB Major Business
    • 2.4.3 UCB Interleukin Inhibitors for Psoriasis Product and Services
    • 2.4.4 UCB Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 UCB Recent Developments/Updates
  • 2.5 Eli Lilly
    • 2.5.1 Eli Lilly Details
    • 2.5.2 Eli Lilly Major Business
    • 2.5.3 Eli Lilly Interleukin Inhibitors for Psoriasis Product and Services
    • 2.5.4 Eli Lilly Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Eli Lilly Recent Developments/Updates
  • 2.6 Novartis
    • 2.6.1 Novartis Details
    • 2.6.2 Novartis Major Business
    • 2.6.3 Novartis Interleukin Inhibitors for Psoriasis Product and Services
    • 2.6.4 Novartis Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Novartis Recent Developments/Updates
  • 2.7 Ortho Dermatologics
    • 2.7.1 Ortho Dermatologics Details
    • 2.7.2 Ortho Dermatologics Major Business
    • 2.7.3 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product and Services
    • 2.7.4 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Ortho Dermatologics Recent Developments/Updates
  • 2.8 LEO Pharma
    • 2.8.1 LEO Pharma Details
    • 2.8.2 LEO Pharma Major Business
    • 2.8.3 LEO Pharma Interleukin Inhibitors for Psoriasis Product and Services
    • 2.8.4 LEO Pharma Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 LEO Pharma Recent Developments/Updates
  • 2.9 Kyowa Kirin
    • 2.9.1 Kyowa Kirin Details
    • 2.9.2 Kyowa Kirin Major Business
    • 2.9.3 Kyowa Kirin Interleukin Inhibitors for Psoriasis Product and Services
    • 2.9.4 Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Kyowa Kirin Recent Developments/Updates
  • 2.10 Samsung Bioepis
    • 2.10.1 Samsung Bioepis Details
    • 2.10.2 Samsung Bioepis Major Business
    • 2.10.3 Samsung Bioepis Interleukin Inhibitors for Psoriasis Product and Services
    • 2.10.4 Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Samsung Bioepis Recent Developments/Updates
  • 2.11 Sun Pharma
    • 2.11.1 Sun Pharma Details
    • 2.11.2 Sun Pharma Major Business
    • 2.11.3 Sun Pharma Interleukin Inhibitors for Psoriasis Product and Services
    • 2.11.4 Sun Pharma Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Sun Pharma Recent Developments/Updates
  • 2.12 China Medical System
    • 2.12.1 China Medical System Details
    • 2.12.2 China Medical System Major Business
    • 2.12.3 China Medical System Interleukin Inhibitors for Psoriasis Product and Services
    • 2.12.4 China Medical System Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 China Medical System Recent Developments/Updates
  • 2.13 Almirall
    • 2.13.1 Almirall Details
    • 2.13.2 Almirall Major Business
    • 2.13.3 Almirall Interleukin Inhibitors for Psoriasis Product and Services
    • 2.13.4 Almirall Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Almirall Recent Developments/Updates
  • 2.14 AbbVie Biotechnology
    • 2.14.1 AbbVie Biotechnology Details
    • 2.14.2 AbbVie Biotechnology Major Business
    • 2.14.3 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product and Services
    • 2.14.4 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 AbbVie Biotechnology Recent Developments/Updates

3 Competitive Environment: Interleukin Inhibitors for Psoriasis by Manufacturer

  • 3.1 Global Interleukin Inhibitors for Psoriasis Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Interleukin Inhibitors for Psoriasis Revenue by Manufacturer (2021-2026)
  • 3.3 Global Interleukin Inhibitors for Psoriasis Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Interleukin Inhibitors for Psoriasis by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Interleukin Inhibitors for Psoriasis Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Interleukin Inhibitors for Psoriasis Manufacturer Market Share in 2025
  • 3.5 Interleukin Inhibitors for Psoriasis Market: Overall Company Footprint Analysis
    • 3.5.1 Interleukin Inhibitors for Psoriasis Market: Region Footprint
    • 3.5.2 Interleukin Inhibitors for Psoriasis Market: Company Product Type Footprint
    • 3.5.3 Interleukin Inhibitors for Psoriasis Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Interleukin Inhibitors for Psoriasis Market Size by Region
    • 4.1.1 Global Interleukin Inhibitors for Psoriasis Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Interleukin Inhibitors for Psoriasis Consumption Value by Region (2021-2032)
    • 4.1.3 Global Interleukin Inhibitors for Psoriasis Average Price by Region (2021-2032)
  • 4.2 North America Interleukin Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.3 Europe Interleukin Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Interleukin Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.5 South America Interleukin Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Interleukin Inhibitors for Psoriasis Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Interleukin Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 5.2 Global Interleukin Inhibitors for Psoriasis Consumption Value by Type (2021-2032)
  • 5.3 Global Interleukin Inhibitors for Psoriasis Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Interleukin Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 6.2 Global Interleukin Inhibitors for Psoriasis Consumption Value by Application (2021-2032)
  • 6.3 Global Interleukin Inhibitors for Psoriasis Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Interleukin Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 7.2 North America Interleukin Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 7.3 North America Interleukin Inhibitors for Psoriasis Market Size by Country
    • 7.3.1 North America Interleukin Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Interleukin Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Interleukin Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 8.2 Europe Interleukin Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 8.3 Europe Interleukin Inhibitors for Psoriasis Market Size by Country
    • 8.3.1 Europe Interleukin Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Interleukin Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Interleukin Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Interleukin Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Interleukin Inhibitors for Psoriasis Market Size by Region
    • 9.3.1 Asia-Pacific Interleukin Inhibitors for Psoriasis Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Interleukin Inhibitors for Psoriasis Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Interleukin Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 10.2 South America Interleukin Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 10.3 South America Interleukin Inhibitors for Psoriasis Market Size by Country
    • 10.3.1 South America Interleukin Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Interleukin Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Interleukin Inhibitors for Psoriasis Market Size by Country
    • 11.3.1 Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Interleukin Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Interleukin Inhibitors for Psoriasis Market Drivers
  • 12.2 Interleukin Inhibitors for Psoriasis Market Restraints
  • 12.3 Interleukin Inhibitors for Psoriasis Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Interleukin Inhibitors for Psoriasis and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Interleukin Inhibitors for Psoriasis
  • 13.3 Interleukin Inhibitors for Psoriasis Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Interleukin Inhibitors for Psoriasis Typical Distributors
  • 14.3 Interleukin Inhibitors for Psoriasis Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Interleukin Inhibitors for Psoriasis. Industry analysis & Market Report on Interleukin Inhibitors for Psoriasis is a syndicated market report, published as Global Interleukin Inhibitors for Psoriasis Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Interleukin Inhibitors for Psoriasis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo